Caveolin-1 deficiency alleviates MCD-induced hepatic steatosis by coordinating ACC inhibitory phosphorylation, cholesterol redistribution and inflammatory remodeling
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive metabolic dysfunction accompanied by persistent hepatic inflammation. Increasing evidence implicates Caveolin-1 (Cav-1) in metabolic diseases; however, whether Cav-1 coordinately regulates hepatic lipid metabolism and inflammatory remodeling during MASLD progression remains unclear. Here, we investigated the pathogenic role and mechanisms of Cav-1 in MASLD using clinical samples and complementary in vivo and in vitro models. Methods Serum Cav-1 was measured in healthy controls and patients with MASLD-related cirrhosis. Dynamic Cav-1 secretion was validated in LPS-challenged RAW264.7 macrophages and MCD-induced MASLD mice. Cav-1 knockout mice and Cav-1-silenced AML-12 hepatocytes were used to investigate Cav-1 functions in hepatic lipid metabolism and inflammatory injury. Hepatic steatosis was evaluated by Oil Red O and Nile Red staining. Systemic and intrahepatic lipid profiles, ABCA1 expression, and the AMPK/ACC lipogenic axis were analyzed to define lipid metabolic reprogramming. Hepatic pathology, myeloid cell infiltration and proinflammatory cytokines were assessed by H&E staining, NAS scoring, Sirius Red staining, flow cytometry and qRT-PCR. Serum transaminases were measured to quantify hepatocellular damage. Results Circulating Cav-1 was significantly increased in patients with MASLD-associated cirrhosis, MCD-fed mice, and LPS-stimulated macrophages, suggesting Cav-1 is induced in response to early metabolic stress. Genetic ablation or silencing of Cav-1 substantially ameliorated hepatic steatosis, hepatocellular injury, and inflammatory responses both in vivo and in vitro . Consistently, Cav-1 deletion alleviated hepatic fibrosis in mice. Mechanistically, Cav-1 deficiency enhanced the inhibitory phosphorylation of acetyl-CoA carboxylase (ACC), suppressing ACC catalytic activity independent of total ACC protein levels and restraining hepatic de novo lipogenesis. In parallel, loss of Cav-1 upregulated hepatic ABCA1 expression to promote cholesterol efflux and facilitate adaptive lipid redistribution between the liver and peripheral circulation. Furthermore, Cav-1 deletion robustly reduced recruitment of proinflammatory monocytes/macrophages and neutrophils, reshaping the proinflammatory hepatic microenvironment. Conclusions Our findings identify Cav-1 as an upstream coordinator of hepatic immunometabolic remodeling during MASLD progression. By concurrently modulating ACC-dependent de novo lipogenesis, ABCA1-mediated cholesterol trafficking, and innate immune cell recruitment, Cav-1 integrates metabolic and inflammatory responses that drive hepatic steatohepatitis and subsequent fibrosis progression. Targeting Cav-1 may therefore represent a promising therapeutic strategy for MASLD.
Authors
- Baian Chen (ORCID: https://orcid.org/0000-0003-3038-4941)
- 严玉霖
- Ruirui Li
- Yixue Shu
- Guoqin Gao
- Quan Sun
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fimmu.2026.1971138
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00